Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Aspirin reduces the risk of colon cancer recurrence after surgery, but only in patients with a specific genetic marker ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

Aspirin has long been used for its analgesic, antipyretic, and antiplatelet properties. Interest in its role in oncology, particularly in CRC, has expanded over time. Its primary mechanism involves ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Recent research from Massachusetts General Hospital and Harvard Medical School has uncovered aspirin‘s surprising protective effect against colorectal cancer, particularly among individuals with less ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be limited to individuals already at risk due to elevations in a particular ...

The National Cancer Institute predicts that colorectal cancers will make up 8% of new cancer cases in 2025, and it is often recurring, so scientists are looking for ways to reduce the risk of it ...

Researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer.